Donate Tissue

Month: February 2022

  • Cell2Cure enters a collaboration agreement with Endeavour Cells ApS

    Cell2Cure enters a collaboration agreement with Endeavour Cells ApS

    Cell2Cure has entered a collaboration agreement with Endeavour Cells ApS, to collaborate on the preparation, conduct, management, and completion of an un-blinded phase I/II clinical trial in children with autism.

    The clinical trial title is “Effect of adipose derived mesenchymal stromal cells on autism and leaky gut syndrome”.

    Endeavour Cells will financially sponsor the trial, but Cell2Cure will have the role as clinical sponsor.

    It is expected that the trial will be ready to enroll the first participant early 2023.

  • Cell2Cure enters a sublicense agreement with Endeavour Cells ApS

    Cell2Cure enters a sublicense agreement with Endeavour Cells ApS

    Cell2Cure has entered a sublicense agreement with Endeavour Cells ApS, which will allow Endeavour Cells ApS to develop, manufacture and commercialize allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs) for the treatment of Autism Spectrum Disorder (ASD), Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Disorder (ADD), and other heterogeneous neurodevelopmental disorders with or without gastrointestinal issues.

    The agreements include down- and milestone payments, and ongoing service, support, and management of the project on undisclosed commercial terms.